Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCREEN: Serplulimab, Chidamide, and Rituximab Followed by R-CHOP in Elderly Double-Expressor DLBCL
NCT07538180Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University. Started Oct 2025; status: active, not recruiting.
02
Drugs
serplulimabtucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07538180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07538180.